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A 73-year-old male patient presented with ocular pain, redness, and blurred vision in the left eye, which
had been ongoing for more than 2 months. An oval-shaped paracentral corneal ulcer with stromal
inﬁltration and a mild anterior chamber reaction were found. Despite treatment with empiric antibiotics,
the lesion progressed and corneal thinning in the middle area was noted. The culture yielded Candida
parapsilosis. We therefore prescribed topical 0.2% ﬂuconazole (FCZ) in combination with oral FCZ as an
antifungal treatment, following which the stromal inﬁltration gradually subsided. Complete epithelial-
ization was noted on the 8th day after initiating FCZ therapy. There was no recurrent disease in the
subsequent 2 years. Our case demonstrates that topical FCZ 0.2% in combination with oral FCZ can
successfully treat C. parapsilosis keratitis and result in a good visual outcome.
Copyright © 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cases of Candida parapsilosis keratitis have been reported in
patients with topical or systemic corticosteroid usage, prior corneal
surgery [e.g., corneal graft or laser-assisted in situ keratomileusis
(LASIK) surgery], or chronic keratopathy.1e5 Although C. parapsilosis
is less virulent than Candida albicans in animal experiments, the
clinical prognosis of C. parapsilosis keratitis is poor and indeed not
better than that of keratitis caused by other Candida species.5
The ﬁrst-line antifungal agent for yeast keratitis is usually
topical amphotericin B (amp B).6 However, previous studies have
shown that most patients with C. parapsilosis keratitis treated with
amp B have poor visual prognosis; furthermore, in these patients,
corneal grafts or anterior chamber washing may be need to eradi-
cate the pathogen.5
Topical azoles [e.g., ﬂuconazole (FCZ) and voriconazole] are
considered to be a good alternative to amp B for the treatment ofe no conﬂicts of interest.
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iety of Taiwan. Published by ElseviCandida keratitis.7e11 It has better ocular penetration and is less
toxic to the corneal epithelium, compared with amp B. In this
report, we present a case of C. parapsilosis keratitis treated suc-
cessfully with topical 0.2% FCZ in combination with oral FCZ.2. Case report
A 73-year-old male patient presented with ocular pain, redness,
and blurred vision in the left eye, which had been ongoing for >
2 months. He had underlying diseases (Type 2 diabetes mellitus
and hypertension) but no ocular trauma or surgery history. His
blood sugar level was well controlled using oral antidiabetic drugs
with hemoglobin A1c levels below 6.5%.
An oval-shaped paracentral corneal ulcer with stromal inﬁltra-
tion (Figure 1) and a mild anterior chamber reaction were found.
The best-corrected visual acuity (BCVA) (oculus sinister) was 0.5
with the Snellen chart. The corneal sensitivity was intact. Despite
treatment with empiric antibiotics, progressive corneal thinning in
the middle area was noted. Initially, we treated him with one drop
of 0.3% ciproﬂoxacin every 2 hours for 4 days but then shifted to
0.3% tobramycin four times daily because of the poor response to
ciproﬂoxacin and concerns about the corneal toxicity of ciproﬂox-
acin. The culture yielded C. parapsilosis on the 11th day. We there-
fore initiated antifungal therapy with topical 0.2% FCZ (Q2h)er Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1. Photograph of the anterior segment showing an oval-shaped paracentral
corneal ulcer with epithelial defect and stromal inﬁltration on the temporal side of the
left eye in our patient with Candida parapsilosis keratitis. This photograph was taken
when the patient initially presented to us.
P.-H. Li et al. / Taiwan Journal of Ophthalmology 6 (2016) 155e157156prepared with an intravenous injectable solution (100 mg/50 mL)
in combination with oral FCZ (100 mg 2 times daily). Of note, the
0.2% FCZ eye drops should be kept in the refrigerator (4C). The
storage life of the FCZ eye drops is 1 week. After 1 week, a new
bottle of FCZ eye drops should be prepared at the time of use.9
After initiation of FCZ therapy, the stromal inﬁltration subsided
gradually (Figure 2). Complete epithelialization was noted on the
8th day after initiating FCZ therapy. There was no recurrent disease
in the following 2 years. Although a paracentral corneal opacity was
found, the BCVA at the 3-month and 2-year follow-ups were 0.7
and 1.0, respectively (Figure 3).
3. Discussion
Infection due to C. parapsilosis is thought to be opportunistic. The
incidence ofC. parapsilosis infection (e.g., fungemia, endocarditis, and
meningitis) has increased dramatically over the past decade, which
may be due to the increasing use of corticosteroids and rising
numbers of immunocompromised patients.12,13 Previous studies
have shown that C. parapsilosis is one of themost commonly cultured
yeasts and are thus commonly detected on the hands of healthcare
workers. Therefore, nosocomial infection is also a possible cause of
the increasing prevalence of C. parapsilosis infection.13
Ocular diseases linked to C. parapsilosis include infectious
keratitis and endophthalmitis. A large case series reported thatFigure 2. (A) Photograph showing progressive corneal thinning in the middle area of the les
FCZ therapy. It can be seen that the size of the epithelial defect, the stromal inﬁltration, anC. parapsilosis accounted for ~10% of all causes of yeast keratitis in
south Florida between 1982 and 1992.14 According to a more recent
study, C. parapsilosis constitutes about 31% of all Candida keratitis
cases.15 Because C. parapsilosis is an emerging fungal pathogen, we
expect that there may be an increase in the number of cases of
ocular infection in the future. Ophthalmologists should therefore
pay attention to, and augment their knowledge of, C. parapsilosis
keratitis.
The possible predisposing factors of C. parapsilosis keratitis are
topical or systemic corticosteroid usage and prior ocular surgery,
such as penetrating keratoplasty, LASIK surgery, or keratoprosthesis
implantation.1e5,16 In our case, the patient had not received any
ocular surgery or systemic steroids. Nevertheless, his topical
medical history was unclear; it is possible that he may have been
exposed to topical corticosteroids due to poor compliance,
although the exposure period would have been short (i.e., not
longer than 1 week). He mentioned frequent visits to hospitals
because of his wife's illness, and therefore, nosocomial infection
due to C. parapsilosis was also a possibility.
The clinical presentation of C. parapsilosis keratitis has shown
great diversity. Patients usually present with symptoms of redness,
photophobia, pain, and decreased vision of variable severity. Some
eyes have a yellow-white inﬁltrate with dry, raised slough, and
feathery edges. Severe keratitis may cause wet, necrotic stromal
inﬂammation to develop with features indistinguishable from
those of other forms of microbial keratitis.5 Infectious crystalline
keratopathy has also been reported in some cases.5,17 Anterior
chamber reactions are variable5 and may combine with
endophthalmitis.12,16
To date, the Cochrane Reviews have reported no evidence that
any particular drug, or combination of drugs, is more effective in
the management of fungal keratitis.18 Conventionally, amp B is the
ﬁrst-line antifungal agent for yeast keratitis; however, the ocular
penetration of amp B is poor. Topical amp B prepared from powder
is irritating for the cornea and toxic to the corneal epithelium.19
Bourcier et al5 reported four cases of C. parapsilosis keratitis
treated with topical amp B with or without adjuvant oral azole
antifungal agents; in their study, two patients needed therapeutic
corneal grafts and one needed anterior chamber washing with
diluted amp B to cure the infection. The other patient needed
further keratoplasty due to persistent corneal opacity. The visual
outcomes ranged from no light perception to 0.5. Chen et al4 re-
ported a case of C. parapsilosis interface keratitis after LASIK sur-
gery; this patient was successfully treated with amp B after which
visual acuity improved to 1.0.
It has also been reported that topical 0.2% FCZ is a safe and
effective antifungal drug for the management of Candida kera-
titis.8,9 The corneal penetration of topical 0.2% FCZ is good; theion before starting antifungal therapy. Photograph taken (B) 2 days and (C) 7 days after
d the depth of the lesion are gradually reduced.
Figure 3. At the 3-month follow-up, complete healing of the corneal epithelium and resolution of the corneal inﬁltration were observed. Although the corneal opacity was evident,
the best-corrected visual acuity at the 2-year follow-up is 1.0.
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tory concentrations of most Candida strains, including
C. parapsilosis. Therefore, topical 0.2% FCZ is thought to be a good
alternative to topical amp B for the treatment of Candida keratitis.11
Matsumoto et al9 compared the efﬁcacy of topical 0.1% micafungin
and topical 0.2% FCZ in the treatment of Candida fungal keratitis
and concluded that the efﬁcacy of 0.1% micafungin eye drops ap-
pears to be comparable with that of 0.2% FCZ eye drops. In their
study, six cases of C. parapsilosis keratitis were treated successfully
with topical 0.2% FCZ as the ﬁrst-line antifungal eye drops, and the
mean healing period was 51 days. In the management of deep
fungal keratitis, oral FCZ is usually considered as an adjuvant
therapy because it is absorbed systemically with good levels in the
anterior chamber and the cornea.20 The recommend dosage of oral
FCZ is 200e400 mg daily.21
Given the inconvenience and side effects of amp B, as well as the
good penetration of FCZ, we prescribed topical 0.2% FCZ in com-
bination with adjuvant oral FCZ for our patient once the culture
yielded the growth of C. parapsilosis. We started from a relatively
low dose (200 mg daily) of oral FCZ because we already prescribed
topical FCZ and due to concerns of a possible drug interaction be-
tween FCZ and glimepiride, an antidiabetic medication that was
used in this patient.22,23 The stroma inﬁltration soon subsided and
the epithelium healed in 8 days. The patient did not have any sig-
niﬁcant side effects to topical 0.2% FCZ.
Experimental studies have generally shown that C. parapsilosis is
less virulent than C. albicans or C. tropicalis; however, poor prog-
noses due to C. parapsilosis keratitis have been reported. This
pathogen may be associated with endophthalmitis and can lead to
graft failure and poor visual outcomes.5,12,16 Early diagnosis and
appropriate antifungal treatment, which can result in good out-
comes, are therefore important.4 Our patient showed an excellent
response to FCZ, and the healing period was much shorter than
those reported previously.9 The visual outcome of our patient was
good and the BCVA was 1.0 at the 2-year follow-up. This may be
attributable to the relatively healthy cornea of our patient and a
successful strategy of antifungal treatment.
4. Conclusion
Cases of C. parapsilosis keratitis are rare. However, it is reported
to occur in patients with compromised cornea or with long-term
corticosteroid use. Although this pathogen is less virulent than
C. albicans, relative poor prognosis and longer healing periods have
been reported. Our case demonstrated that topical FCZ (0.2%) in
combination with oral FCZ could successfully treat C. parapsilosis
keratitis and result in good visual outcome.References
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